<DOC>
	<DOCNO>NCT02479646</DOCNO>
	<brief_summary>This single center , double-blind , randomize , comparative pharmacokinetic pharmacodynamic study MYL-1401H Neulasta ( EU US source ) Normal Healthy Volunteers .</brief_summary>
	<brief_title>Pharmacokinetic / Pharmacodynamic Study Comparing MYL-1401H , EU-sourced Neulasta US-licensed Neulasta</brief_title>
	<detailed_description>After successful screening , subject randomly allocate one follow six possible sequence , accord 1:1:1:1:1:1 randomization scheme : Sequence_1 : Treatment A - &gt; Treatment B - &gt; Treatment C ; Sequence_2 : Treatment A - &gt; Treatment C - &gt; Treatment B ; Sequence_3 : Treatment B - &gt; Treatment A - &gt; Treatment C ; Sequence_4 : Treatment B - &gt; Treatment C - &gt; Treatment A ; Sequence_5 : Treatment C - &gt; Treatment A - &gt; Treatment B ; Sequence_6 : Treatment C - &gt; Treatment B - &gt; Treatment A ; In study Period 1 , Subjects administer MYL-1401H ( Treatment A ) , EU-Neulasta ( Treatment B ) US-Neulasta ( Treatment C ) . After 1st crossover , subject enter Study period 2 receive one remain alternate treatment . After 2nd crossover , subject enter Study period 3 receive alternate treatment . The washout drug administration least 4 week . Final follow-up visit schedule 4 week last study drug administration .</detailed_description>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Weight : ≥60 kg . Body mass index ( BMI ) : 19.030.0 kg/m2 Vital sign show clinically relevant deviation . Computerized 12lead ECG record without sign clinically relevant pathology . Nonsmoker light smoker Ability willingness abstain alcohol 48 hour prior admission clinical research center prior ambulatory visit , stay clinic . Fertile male females participate heterosexual sexual relation : willingness use adequate contraception screen 90 day follow visit Females must lactate must negative pregnancy test screen admission . ANC , total leukocyte count , platelet count , hematocrit hemoglobin result within reference range . All value hematology clinical chemistry test blood urine within normal range show clinically relevant deviation judge Principal Investigator Other protocol specific inclusion/exclusion criterion may apply Unable follow protocol instruction opinion Principal Investigator . Any past concurrent medical condition potentially increase subject 's risk affect evaluation study result . Examples include medical history evidence clinically relevant pathology ( e.g . sickle cell disorder , spleen pathology , hematologic malignancy myelodysplastic disorder , pulmonary illness ARDS , interstitial pneumonia , pulmonary edema , pulmonary infiltrates pulmonary fibrosis ) history relevant drug and/or food allergy . Known history previous exposure filgrastim , pegfilgrastim , granulocyte colony stimulate factor ( GCSF ) analogue . Hypersensitivity constituent Neulasta® ( sorbitol E420 , polysorbate 20 acetate acetic acid ) hypersensitivity E. coli derive protein . Any infection , cough fever within 1 week prior first study drug administration . Fructose intolerance . First degree relative hematological malignancy . Treatment nontopical medication within 5 day prior first admission clinical research center , exception hormonal contraceptive , multivitamin , vitamin C , food supplement limit amount paracetamol ( acetaminophen ) , may use throughout study . Participation drug study within 60 day prior study drug administration . Donation loss 500 mL blood period 60 day prior study drug administration . Donation 1.5 L blood ( men ) / 1.0 L blood ( woman ) 10 month precede start study . History alcohol abuse drug addiction Regular intake 24 unit alcohol per week ( one unit alcohol equal approximately 250 mL beer , 100 mL wine 35 mL spirit ) . Positive drug screen ( opiate , methadone , cocaine , amphetamine ( include ecstasy ) , cannabinoids , barbiturate , benzodiazepine , tricyclic antidepressant alcohol ) . Positive screen hepatitis B surface antigen ( HBsAg ) , antihepatitis C virus ( HCV ) antibody , antihuman immunodeficiency virus ( HIV ) 1/2 antibody . Other protocol specific inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Pegfilgrastim</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>